Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1Ab21-CD19 CAR-T
- Development stage
- Unknown
- Lead developer
- BRL Medicine
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
PD-1Ab21-CD19 CAR-T (also known as BRL-201) is an autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target CD19-positive B-cell malignancies while simultaneously secreting a bifunctional fusion protein (PD-1Ab21) that consists of a PD-1-blocking antibody and Interleukin-21 (IL-21). Developed by BRL Medicine in collaboration with researchers at Soochow University, this therapy is designed to overcome the limitations of conventional CAR-T cells, such as exhaustion and poor persistence, by providing localized checkpoint inhibition and cytokine support within the tumor microenvironment. In Phase 1 clinical trials for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), PD-1Ab21-CD19 CAR-T has demonstrated a manageable safety profile and significant antitumor activity, including high rates of complete metabolic remission and improved durability compared to standard CD19-directed therapies.
- Other names
- PD-1AB21-EXPRESSING, ANTI-CD19 CAR T CELLS
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1Ab21-CD19 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1Ab21-CD19 CAR-T.